Singapore markets close in 6 hours 2 minutes
Straits Times Index
3,287.33 +21.38 (+0.65%) Nikkei
38,311.63 +237.65 (+0.62%) Hang Seng
18,760.27 +222.46 (+1.20%) FTSE 100
8,381.35 +27.30 (+0.33%) Bitcoin USD
62,837.74 +1,196.83 (+1.94%) CMC Crypto 200
1,352.17 +52.07 (+4.01%)
Revolution Medicines, Inc. (RVMD)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
Currency in USD
Valuation measures4
| Market cap (intra-day) | 6.53B |
| Enterprise value | 4.77B |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG ratio (5-yr expected) | N/A |
| Price/sales (ttm) | 374.33 |
| Price/book (mrq) | 3.58 |
| Enterprise value/revenue | 411.62 |
| Enterprise value/EBITDA | -11.08 |
Trading information
Stock price history
| Beta (5Y monthly) | N/A |
| 52-week change 3 | 44.76% |
| S&P500 52-week change 3 | 26.43% |
| 52-week high 3 | 40.21 |
| 52-week low 3 | 15.44 |
| 50-day moving average 3 | 33.86 |
| 200-day moving average 3 | 29.00 |
Share statistics
| Avg vol (3-month) 3 | 1.49M |
| Avg vol (10-day) 3 | 1.15M |
| Shares outstanding 5 | 164.99M |
| Implied shares outstanding 6 | 174.27M |
| Float 8 | 161M |
| % held by insiders 1 | 2.29% |
| % held by institutions 1 | 93.65% |
| Shares short (15 Apr 2024) 4 | 12.49M |
| Short ratio (15 Apr 2024) 4 | 7.78 |
| Short % of float (15 Apr 2024) 4 | 7.80% |
| Short % of shares outstanding (15 Apr 2024) 4 | 7.33% |
| Shares short (prior month 15 Mar 2024) 4 | 16.4M |
Dividends & splits
| Forward annual dividend rate 4 | N/A |
| Forward annual dividend yield 4 | N/A |
| Trailing annual dividend rate 3 | 0.00 |
| Trailing annual dividend yield 3 | 0.00% |
| 5-year average dividend yield 4 | N/A |
| Payout ratio 4 | 0.00% |
| Dividend date 3 | N/A |
| Ex-dividend date 4 | N/A |
| Last split factor 2 | N/A |
| Last split date 3 | N/A |
Financial highlights
Fiscal year
| Fiscal year ends | 31 Dec 2023 |
| Most-recent quarter (mrq) | 31 Mar 2024 |
Profitability
| Profit margin | 0.00% |
| Operating margin (ttm) | -11,550.31% |
Management effectiveness
| Return on assets (ttm) | N/A |
| Return on equity (ttm) | N/A |
Income statement
| Revenue (ttm) | 4.57M |
| Revenue per share (ttm) | 0.04 |
| Quarterly revenue growth (yoy) | N/A |
| Gross profit (ttm) | N/A |
| EBITDA | -522.3M |
| Net income avi to common (ttm) | -484.27M |
| Diluted EPS (ttm) | -3.84 |
| Quarterly earnings growth (yoy) | N/A |
Balance sheet
| Total cash (mrq) | N/A |
| Total cash per share (mrq) | N/A |
| Total debt (mrq) | N/A |
| Total debt/equity (mrq) | 4.82% |
| Current ratio (mrq) | N/A |
| Book value per share (mrq) | 11.09 |
Cash flow statement
| Operating cash flow (ttm) | N/A |
| Levered free cash flow (ttm) | N/A |
© 2024 Yahoo. All rights reserved.